PL3915989T3 - Inhibitor jak i sposób jego otrzymywania - Google Patents
Inhibitor jak i sposób jego otrzymywaniaInfo
- Publication number
- PL3915989T3 PL3915989T3 PL19913097.2T PL19913097T PL3915989T3 PL 3915989 T3 PL3915989 T3 PL 3915989T3 PL 19913097 T PL19913097 T PL 19913097T PL 3915989 T3 PL3915989 T3 PL 3915989T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- method therefor
- jak inhibitor
- jak
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910088713 | 2019-01-30 | ||
| PCT/CN2019/127494 WO2020155931A1 (zh) | 2019-01-30 | 2019-12-23 | 一种jak抑制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3915989T3 true PL3915989T3 (pl) | 2023-12-11 |
Family
ID=71839941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19913097.2T PL3915989T3 (pl) | 2019-01-30 | 2019-12-23 | Inhibitor jak i sposób jego otrzymywania |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12509463B2 (pl) |
| EP (1) | EP3915989B1 (pl) |
| JP (1) | JP7278649B6 (pl) |
| KR (1) | KR102857917B1 (pl) |
| CN (1) | CN111499641B (pl) |
| AU (1) | AU2019426113B2 (pl) |
| BR (1) | BR112021014525A8 (pl) |
| CA (1) | CA3127892A1 (pl) |
| CO (1) | CO2021010415A2 (pl) |
| DK (1) | DK3915989T3 (pl) |
| ES (1) | ES2958160T3 (pl) |
| FI (1) | FI3915989T3 (pl) |
| MX (1) | MX2021008984A (pl) |
| PH (1) | PH12021551844A1 (pl) |
| PL (1) | PL3915989T3 (pl) |
| PT (1) | PT3915989T (pl) |
| WO (1) | WO2020155931A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118255769A (zh) | 2022-12-28 | 2024-06-28 | 格格巫（珠海）生物科技有限公司 | 一种立体异构体的制备方法及中间体 |
| CN118420617A (zh) * | 2023-01-31 | 2024-08-02 | 格格巫（珠海）生物科技有限公司 | 一种化合物的晶型及其制备方法和用途 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4442111A (en) | 1981-07-25 | 1984-04-10 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Antithrombotic sulfimino and sulfoximino indolinones-2 |
| WO2005085249A1 (en) * | 2004-02-27 | 2005-09-15 | F. Hoffmann-La Roche Ag | Fused derivatives of pyrazole |
| ES2385118T3 (es) | 2008-01-17 | 2012-07-18 | Bayer Pharma Aktiengesellschaft | Derivados de quinazolina sustituida con sulfoximina como inmunomoduladores, su preparación y uso como medicamentos |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| KR101335843B1 (ko) * | 2008-08-20 | 2013-12-02 | 조에티스 엘엘씨 | 피롤로[2,3-ｄ]피리미딘 화합물 |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| JP5658756B2 (ja) | 2009-09-10 | 2015-01-28 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊａｋの阻害剤 |
| ES2426407T3 (es) | 2009-10-15 | 2013-10-23 | Pfizer Inc. | Compuestos de pirrolo[2,3-d]pirimidina |
| WO2011075334A1 (en) * | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| WO2011078143A1 (ja) * | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| EP2360158A1 (en) | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| EA201490230A1 (ru) | 2011-07-08 | 2014-06-30 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч | Применение меченых ингибиторов hsp90 |
| CA2849345A1 (en) | 2011-09-23 | 2013-03-28 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| CN108354938A (zh) * | 2012-07-20 | 2018-08-03 | 硕腾服务有限责任公司 | Janus激酶（jak）抑制剂的给药方案 |
| GEP201606600B (en) | 2013-02-22 | 2017-01-10 | Pfizer | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) |
| WO2014146246A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors |
| CN105189508B (zh) * | 2013-03-19 | 2018-11-23 | 默沙东公司 | 作为janus激酶抑制剂的环烷基腈吡唑并吡啶酮 |
| WO2014146249A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
| US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| EA036122B1 (ru) | 2015-01-20 | 2020-09-30 | Уси Форчун Фармасьютикал Ко., Лтд | Ингибитор jak |
| TWI788655B (zh) | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| AU2016254385B2 (en) | 2015-04-29 | 2018-05-10 | Wuxi Fortune Pharmaceutical Co., Ltd | JAK inhibitors |
| KR102081272B1 (ko) | 2015-05-29 | 2020-02-25 | 우시 포춘 파마슈티컬 컴퍼니 리미티드 | Janus 키나아제 억제제 |
| CN105153150B (zh) | 2015-08-14 | 2016-09-14 | 天津小新医药科技有限公司 | 一类吡啶盐类jak抑制剂、制备方法及其用途 |
| US10973913B2 (en) | 2016-02-16 | 2021-04-13 | Washington University | JAK inhibitors and uses thereof |
| EP3416965B1 (en) * | 2016-02-16 | 2020-10-07 | Zoetis Services LLC | Process for preparing 7h-pyrrolo [2,3-d]pyrimidine compounds |
| CN107759600A (zh) | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| CA3055233C (en) * | 2017-01-23 | 2022-08-09 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Jak kinase inhibitor and preparation method and use thereof |
| ES2900199T3 (es) * | 2017-03-28 | 2022-03-16 | Bayer Ag | Novedosos compuestos macrocíclicos inhibidores de PTEFB |
| EP3768272B1 (en) | 2018-03-21 | 2025-07-30 | Xibin Liao | Jak inhibitors |
| AU2020428591B2 (en) | 2020-02-13 | 2024-05-23 | Zhuhai United Laboratories Co., Ltd. | Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases |
-
2019
- 2019-12-23 MX MX2021008984A patent/MX2021008984A/es unknown
- 2019-12-23 PL PL19913097.2T patent/PL3915989T3/pl unknown
- 2019-12-23 JP JP2021543513A patent/JP7278649B6/ja active Active
- 2019-12-23 BR BR112021014525A patent/BR112021014525A8/pt unknown
- 2019-12-23 EP EP19913097.2A patent/EP3915989B1/en active Active
- 2019-12-23 KR KR1020217027469A patent/KR102857917B1/ko active Active
- 2019-12-23 PT PT199130972T patent/PT3915989T/pt unknown
- 2019-12-23 CA CA3127892A patent/CA3127892A1/en active Pending
- 2019-12-23 DK DK19913097.2T patent/DK3915989T3/da active
- 2019-12-23 WO PCT/CN2019/127494 patent/WO2020155931A1/zh not_active Ceased
- 2019-12-23 US US17/426,933 patent/US12509463B2/en active Active
- 2019-12-23 AU AU2019426113A patent/AU2019426113B2/en active Active
- 2019-12-23 FI FIEP19913097.2T patent/FI3915989T3/fi active
- 2019-12-23 CN CN201911336860.1A patent/CN111499641B/zh active Active
- 2019-12-23 PH PH1/2021/551844A patent/PH12021551844A1/en unknown
- 2019-12-23 ES ES19913097T patent/ES2958160T3/es active Active
-
2021
- 2021-08-09 CO CONC2021/0010415A patent/CO2021010415A2/es unknown
-
2025
- 2025-11-25 US US19/400,591 patent/US20260078129A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7278649B2 (ja) | 2023-05-22 |
| KR102857917B1 (ko) | 2025-09-10 |
| PH12021551844A1 (en) | 2022-05-23 |
| BR112021014525A8 (pt) | 2022-11-22 |
| JP7278649B6 (ja) | 2024-02-15 |
| CO2021010415A2 (es) | 2021-08-19 |
| CN111499641A (zh) | 2020-08-07 |
| EP3915989A1 (en) | 2021-12-01 |
| KR20210120074A (ko) | 2021-10-06 |
| NZ779252A (en) | 2024-04-26 |
| CN111499641B (zh) | 2021-06-04 |
| BR112021014525A2 (pt) | 2021-09-28 |
| PT3915989T (pt) | 2023-10-02 |
| DK3915989T3 (da) | 2023-09-18 |
| JP2022518821A (ja) | 2022-03-16 |
| CA3127892A1 (en) | 2020-08-06 |
| AU2019426113A1 (en) | 2021-09-09 |
| AU2019426113B2 (en) | 2022-06-16 |
| MX2021008984A (es) | 2021-09-08 |
| EP3915989A4 (en) | 2022-03-09 |
| US20220106319A1 (en) | 2022-04-07 |
| WO2020155931A1 (zh) | 2020-08-06 |
| ES2958160T3 (es) | 2024-02-02 |
| US12509463B2 (en) | 2025-12-30 |
| EP3915989B1 (en) | 2023-06-28 |
| US20260078129A1 (en) | 2026-03-19 |
| FI3915989T3 (fi) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3915989T (pt) | Inibidor de jak e método de preparação do mesmo | |
| ZA202106511B (en) | Jak inhibitor compound and use thereof | |
| ZA202001447B (en) | M-diamide compound and preparation method therefor and use thereof | |
| IL325537A (en) | Iraq inhibitor and its preparation and use | |
| GB2591554B (en) | Composiitons and methods and uses relating thereto | |
| IL287876A (en) | Jak inhibitors | |
| GB2585849B (en) | Spectrometer and method | |
| GB201903827D0 (en) | New compounds and methods | |
| GB201903832D0 (en) | New compounds and methods | |
| GB202015044D0 (en) | New compounds and methods | |
| GB202015035D0 (en) | New compounds and methods | |
| IL289586A (en) | pi4kiii alpha micromolecule inhibiting preparation, method for its preparation and use | |
| IL291611A (en) | Jak inhibitors | |
| PL4010269T3 (pl) | Kompozycja do natryskiwania i metoda | |
| GB201913110D0 (en) | New compounds and methods | |
| GB2579687B (en) | Composition and method | |
| GB201911916D0 (en) | Compostion and method | |
| GB201913639D0 (en) | Kit and method of using kit | |
| IL290381A (en) | Jak inhibitors | |
| GB202113588D0 (en) | New compounds and methods | |
| GB201914777D0 (en) | Composition and method | |
| GB201911790D0 (en) | method and compostion | |
| GB201913565D0 (en) | New compounds and methods | |
| GB201909036D0 (en) | New compounds and methods | |
| GB202113589D0 (en) | New compounds and methods |